GeneDx Holdings Corp. (WGS) KPIs and segments
Close on Nov 16, 2026Market cap $1.52BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive GeneDx's business
GeneDx's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GeneDx Segment($M) | 114 | 103 | |||||||||||
Gene Dx($M)5 | 101 | 119 | 115 | 102 | 87.1 | 95.3 | 76.6 | 68.9 | 61.5 | 58.1 | 50.4 | ||
Diagnostic test revenue:($M) | 101 | 117 | 113 | 99.8 | 85.8 | 93.8 | 77.2 | 67.8 | 60.1 | 55.9 | 49.0 | ||
Patients with third-party insurance($M) | 84.9 | 101 | 95.0 | 81.1 | 68.1 | 78.9 | 59.3 | 50.5 | 42.9 | 43.5 | 32.8 | ||
Institutional customers($M) | 15.5 | 15.5 | 17.5 | 18.4 | 17.6 | 14.3 | 17.4 | 16.7 | 16.7 | 12.0 | 15.7 | ||
Other revenue($M) | 0.76 | 2.63 | 1.50 | 1.96 | 1.36 | 1.44 | -0.54 | 1.08 | 1.32 | 2.20 | 1.35 | ||
Self-pay patients($M) | 0.29 | 0.30 | 0.63 | 0.34 | 0.10 | 0.60 | 0.46 | 0.69 | 0.59 | 0.47 | 0.46 | ||
Other($M)5 | 0.76 | 2.05 | 0.91 | 0 | 0.25 | 1.59 | 0.96 | 2.95 | |||||
Diagnostic test revenue:($M) | 0.57 | 0.33 | 0 | 0 | 0.25 | 1.59 | 0.96 | 2.95 | |||||
Institutional customers($M) | 0.57 | 0.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Other revenue($M) | 0.19 | 1.72 | 0.91 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Patients with third-party insurance($M) | 0 | 0 | 0 | 0 | 0.25 | 1.59 | 0.96 | 2.95 | |||||
Self-pay patients($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | |||||
Diagnostic test revenue:($M) | 112 | 101 | 117 | 114 | 100 | 85.8 | 94.2 | 77.4 | 69.4 | 61.1 | 55.2 | 52.0 | |
Patients with third-party insurance($M) | 94.7 | 84.9 | 101 | 95.0 | 81.1 | 68.1 | 79.3 | 59.5 | 52.1 | 43.8 | 42.8 | 35.8 | |
Institutional customers($M) | 16.1 | 16.1 | 15.9 | 17.9 | 18.7 | 17.6 | 14.3 | 17.4 | 16.7 | 16.7 | 12.0 | 15.7 | |
Other revenue($M) | 2.55 | 0.96 | 3.70 | 3.22 | 2.59 | 1.36 | 1.44 | -0.54 | 1.08 | 1.32 | 2.20 | 1.35 | |
Self-pay patients($M) | 1.04 | 0.29 | 0.30 | 0.63 | 0.34 | 0.10 | 0.60 | 0.46 | 0.69 | 0.59 | 0.43 | 0.46 | |
Gene Dx($M) | 69.9 | 85.0 | 84.5 | 71.8 | 59.7 | 66.9 | 49.3 | 42.4 | 37.4 | 32.5 | 24.3 | ||
Other($M) | 0.17 | 0 | 0.25 | 1.45 | 0.96 | -0.69 | 2.73 | ||||||
Earlier reporting (last reported 2026)3 | |||||||||||||
8 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-03.
See a number that looks wrong?